UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

Ophthalmology (Rochester, Minn.), 2014-10, Vol.121 (10), p.1904-1914

2014

Volltextzugriff (PDF)

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

JAMA : the journal of the American Medical Association, 2023-02, Vol.329 (5), p.376

2023

Volltextzugriff (PDF)

Rationale for the Diabetic Retinopathy Clinical Research Network Treatment Protocol for Center-Involved Diabetic Macular Edema

Ophthalmology (Rochester, Minn.), 2011-12, Vol.118 (12), p.e5-e14

2011

Volltextzugriff (PDF)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

International journal of retina and vitreous, 2023-01, Vol.9 (1), p.1-1, Article 1

2023

Volltextzugriff (PDF)

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

American journal of ophthalmology, 2003-11, Vol.136 (5), p.791-796

2003

Volltextzugriff (PDF)

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial

JAMA ophthalmology, 2021-07, Vol.139 (7), p.701

2021

Volltextzugriff (PDF)

Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-Reply

JAMA : the journal of the American Medical Association, 2023-05, Vol.329 (20), p.1796

2023

Volltextzugriff (PDF)

Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study

International journal of retina and vitreous, 2021-02, Vol.7 (1), p.11-11, Article 11

2021

Volltextzugriff (PDF)

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study

Ophthalmology (Rochester, Minn.), 2020-10, Vol.127 (10), p.1331

2020

Volltextzugriff (PDF)

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

Ophthalmology science (Online), 2021-09, Vol.1 (3), p.100040-100040, Article 100040

2021

Volltextzugriff (PDF)

PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA

Retina (Philadelphia, Pa.), 2016-10, Vol.36 (10), p.1986-1996

2016

Volltextzugriff (PDF)

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: Three-Year Randomized Trial Results

Ophthalmology (Rochester, Minn.), 2012-11, Vol.119 (11), p.2312-2318

2012

Volltextzugriff (PDF)

A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY

Retina (Philadelphia, Pa.), 2015-08, Vol.35 (8), p.1604-1614

2015

Volltextzugriff (PDF)

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

Ophthalmology science (Online), 2022-06, Vol.2 (2), p.100154-100154, Article 100154

2022

Volltextzugriff (PDF)

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial

JAMA ophthalmology, 2018-01, Vol.136 (1), p.29

2018

Volltextzugriff (PDF)

Plasticity of visual attention in Isha yoga meditation practitioners before and after a 3-month retreat

Frontiers in psychology, 2013, Vol.4, p.914-914

2013

Volltextzugriff (PDF)

Therapeutic Options in Refractory Diabetic Macular Oedema

Drugs (New York, N.Y.), 2017-04, Vol.77 (5), p.481-492

2017

Volltextzugriff (PDF)

INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY

Retina (Philadelphia, Pa.), 2016-06, Vol.36 (6), p.1143-1152

2016

Volltextzugriff (PDF)

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40

Ophthalmology (Rochester, Minn.), 2024-08, Vol.131 (8), p.967-974

2024

Volltextzugriff (PDF)

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

Eye (London), 2024-04, Vol.38 (6), p.1140-1148

2024

Volltextzugriff (PDF)

Retrospective Large Database Study of Central Serous Chorioretinopathy Treatments and Visual Outcomes Analysis in the United States

Journal of vitreoretinal diseases (Print), 2024-09, Vol.8 (5), p.508-516

2024

Volltextzugriff (PDF)

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration

Ophthalmology (Rochester, Minn.), 2021-07, Vol.128 (7), p.1027-1038

2021

Volltextzugriff (PDF)

Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH

Ophthalmology (Rochester, Minn.), 2021-11, Vol.128 (11), p.1592-1603

2021

Volltextzugriff (PDF)

DEFINING "STRONG" VERSUS "WEAK" RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR CENTER-INVOLVED DIABETIC MACULAR EDEMA

Retina (Philadelphia, Pa.), 2023-04, Vol.43 (4), p.616-623

2023

Volltextzugriff (PDF)

Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

Journal of clinical medicine, 2024-09, Vol.13 (18), p.5540

2024

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(82)
Berichte
(1)

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(60)
Science & Technology
(60)
Ophthalmology
(55)
Humans
(47)
Female
(31)
Male
(31)
Middle Aged
(28)
Aged
(24)
Diabetic Retinopathy - Drug Therapy
(19)
Visual Acuity
(19)
Diabetic Retinopathy
(18)
Intravitreal Injections
(16)
Macular Edema - Drug Therapy
(16)
Angiogenesis Inhibitors - Therapeutic Use
(14)
Biological And Medical Sciences
(14)
Diabetes
(13)
Medical Sciences
(13)
Tomography, Optical Coherence
(13)
Treatment Outcome
(13)
Adult
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

Rationale for the Diabetic Retinopathy Clinical Research Network Treatment Protocol for Center-Involved Diabetic Macular Edema

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial

Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-Reply

Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: Three-Year Randomized Trial Results

A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial

Plasticity of visual attention in Isha yoga meditation practitioners before and after a 3-month retreat

Therapeutic Options in Refractory Diabetic Macular Oedema

INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

Retrospective Large Database Study of Central Serous Chorioretinopathy Treatments and Visual Outcomes Analysis in the United States

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration

Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH

DEFINING "STRONG" VERSUS "WEAK" RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR CENTER-INVOLVED DIABETIC MACULAR EDEMA

Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration

Suchergebnisse filtern